Article
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Nov 2011
Martínez-Navarro E M, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández F J, Forteza J, Brugarolas A
Abstract excerpt
INTRODUCTION Epidermal growth factor receptor (EGFR) mutation related to tyrosine kinase inhibitors' (TKIs) responsiveness in non-small cell lung cancer (NSCLC) has become an important issue for therapeutic decision-making in NSCLC patients. MATERIAL AND METHODS Sixty-nine Caucasian NSCLC patients were screened for mutations in the tyrosine kinase (TK) domain of EGFR by direct sequencing from December 2005 to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.